Even patients with low fracture risk benefit from bisphosphonates, NICE says

Osteoporosis patients with a risk of fracture above 1% could benefit from bisphosphonates, NICE has said, but charities have called for GPs to be given more guidance on prescribing.

Bisphosphonates are cost effective even in people with very low risk of fracture, NICE has concluded in its latest technology appraisal.

Oral bisphosphonates should be considered to treat osteoporosis in adults with a 10-year probability of related fracture as low as 1% – as according to the FRAX or QFracture risk tools, it said.

Intravenous bisphosphonates are recommended if risk of fracture is above 10%, or if a patient with a risk over 1% cannot take or tolerate the oral version.

It adds that the choice of treatment should be made on an individual basis after a discussion between the responsible clinician and the patient.

Bisphosphonates – including alendronic acid, risedronate, ibandronate and zoledronic acid – are the most common group of drugs used to treat osteoporosis.

Fracture risk

The revamped recommendations apply to men as well as women, and come in light of a new meta-analysis confirming that bisphosphonates are more effective at reducing the risk of fracture compared to placebo.

The National Osteoporosis Society warned GPs that – although the drugs are clinically and cost effective – they may not be appropriate for every patient with a low fracture risk.

‘There is a risk that if the [technology appraisal] is not correctly applied people could receive a treatment when they don’t need one,’ it said.

‘With growing concerns about possible rare long-term effects of bisphosphonate treatments, we want to make sure that people are only given a treatment when the benefits of treatment outweigh the risks.

‘Health professionals, especially non-specialists like GPs, may need some additional guidance to support their decisions about which patients should be offered a bisphosphonate.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP funding rose much faster in rest of UK than England in 2018/19

GP funding rose much faster in rest of UK than England in 2018/19

Total NHS investment in general practice in England rose just 1.36% in real terms...

GP funding per patient rose less than 2% in 2018/19

GP funding per patient rose less than 2% in 2018/19

GP funding per patient in England rose to £154.81 in 2018/19 - up just 1.8% from...

Temporary cap extended on GP at Hand registrations in Birmingham

Temporary cap extended on GP at Hand registrations in Birmingham

A temporary cap on patients in Birmingham registering with Babylon GP at Hand has...

NHS focus on high-achievers could leave 'immature' PCNs behind

NHS focus on high-achievers could leave 'immature' PCNs behind

Primary care networks (PCNs) formed by practices with little or no history of working...

Should GPs treat patients presenting with dental problems?

Should GPs treat patients presenting with dental problems?

The MDU's Dr Sissy Frank considers what GPs should do if a patient presents with...

Doctors' leaders join forces with GMC to demand specialist recognition for GPs

Doctors' leaders join forces with GMC to demand specialist recognition for GPs

BMA and RCGP leaders have linked up with the GMC to ramp up pressure on the government...